Table of Contents

Orgovyx (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the FDA in 2020 for adult patients with advanced prostate cancer. It rapidly lowers testosterone, which is a hormone that helps certain prostate cancer cells grow. Orgovyx controls disease progression without the initial hormone flare seen with some injectable therapies.

Many men appreciate the convenience of once-daily tablets and the avoidance of injection-site problems. However, like any androgen deprivation therapy (ADT), Orgovyx can cause side effects.

Orgovyx commonly causes hot flashes, fatigue, muscle pain, and metabolic changes such as increased blood sugar and cholesterol. It may also raise cardiovascular and bone fracture risk over time. Most side effects are manageable, but chest pain, stroke symptoms, or severe allergic swelling require immediate medical attention.

Being aware of these reactions encourages early management and reduces anxiety. It also promotes better communication with physicians when serious symptoms arise.

Key Takeaways

  • Most men experience side effects like hot flashes (54%), fatigue (26%), muscle and joint pain (30%), and bowel changes (12%), but only 3.5% stop treatment due to side effects.
  • Blood sugar, cholesterol, and red blood cell levels can change, so routine lab monitoring is necessary during treatment.
  • Heart risks exist, including heart attack and stroke, though clinical trials showed fewer major cardiovascular events compared to leuprolide.
  • Bone density declines over time, increasing fracture risk, which makes weight-bearing exercise and bone monitoring important.
  • Seek emergency care immediately for chest pain, stroke symptoms, severe swelling of the face or throat, or signs of internal bleeding.

Common Orgovyx Side Effects

Clinical trials (the phase 3 HERO study) and post-marketing reports show that many people tolerate Orgovyx well, although most experience some degree of side effects. In the pivotal trial, 93% of participants had at least one adverse event, and 12% had a serious event. Importantly, only about 3.5% discontinued therapy because of adverse reactions.

Hot flashes

More than half of men taking Orgovyx experience sudden warmth or sweating. The HERO trial reported hot flashes in 54% of patients taking relugolix and 51.6% with leuprolide (an injectable GnRH agonist), confirming that vasomotor symptoms are common across ADT.

Hot flashes often occur in waves and may be triggered by stress, caffeine, spicy foods, or warm environments. Try to keep your body cool as much as possible. At night, you might find relief using a “chill pillow” that contains water or a cooling gel. During the day, turn on a fan and dress in light, loose clothing made from breathable fabrics like cotton.

You can also practice slow, deep belly breathing. Aim for about 6 to 8 breaths per minute. Try doing this for 15 minutes in the morning, 15 minutes in the evening, and again when you feel a hot flash coming on.

Some people look into acupuncture as well. While results vary, a few find it helpful for symptom relief.

Certain medications may help when symptoms are severe. Low doses of antidepressants such as venlafaxine have been shown to reduce hot flashes. Another option is gabapentin, a medication originally used for seizures that can also ease hot flash symptoms in some people.

These medications are not FDA-approved specifically for hot flashes. When used for this purpose, it’s considered off-label, so it’s important to talk with your doctor about whether they’re appropriate for you and to review potential risks and benefits.

Laboratory abnormalities

Testosterone is a vital hormone with many functions, including regulating blood sugar, fat metabolism, and red blood cell production. But because Orgovyx lowers testosterone very effectively, several downstream effects can happen.

Laboratory abnormalities from the HERO trial showed that 44% of participants on Orgovyx had increased glucose and 35% had elevated triglycerides. About 18-28% had mild increases in liver enzymes, and around 28% had lower red blood cell levels.

These effects are not unique to Orgovyx. They are expected with any therapy that lowers testosterone.

Regular monitoring of fasting glucose and lipids is recommended, especially in men with diabetes or pre-existing dyslipidemia. Lifestyle adjustments such as reducing refined carbohydrates, increasing fiber intake, and engaging in regular aerobic exercise can help maintain healthy metabolic numbers.

Weight gain and muscle loss

Orgovyx Side Effects Explained

Testosterone also supports muscle mass and fat metabolism. So, when levels drop, body composition shifts toward more fat and less lean mass.

According to studies, men with prostate cancer who receive ADT can develop sarcopenic obesity. This happens when a person has both excess body fat and reduced muscle mass or strength at the same time.

In a patient testimony, men described gaining fat while losing muscle, feeling weak and fatigued, and finding daily activities like walking up stairs more difficult.

Exercise and nutrition are important to counter these effects. Combining aerobic and resistance exercise (multi-modal programs) produces the most consistent improvements in both fat loss and muscle preservation.

Adding a nutrition component, especially creating a calorie deficit with protein optimization, is also effective for reducing fat mass while also preserving lean mass during weight loss.

Tracking weight, waist circumference, and body composition with your care team is useful for early intervention.

Diarrhea or constipation

Hormone changes can also disrupt normal bowel regulation. In some people, this change speeds up bowel movements, leading to diarrhea. In others, it slows things down, leading to constipation. Depending on how a person’s body responds, it can go in either direction.

The HERO trial reported diarrhea in 12% of patients taking Orgovyx. Constipation also occurred in about 12% of patients. All cases were mild to moderate, and none led to treatment withdrawal.

For diarrhea, adjusting diet to include BRAT foods (bananas, rice, applesauce, and toast) and staying hydrated may help. Loperamide is an OTC remedy for bothersome diarrhea.

For constipation, adequate fiber intake, hydration, and gentle activity such as walking can keep bowel movements regular. If constipation persists, speak with your doctor about stool softeners or laxatives.

Fatigue and physical weakness

Fatigue, including asthenia or physical weakness or lack of strength, affected around 26% of trial participants. Patients describe fatigue as one of the most bothersome aspects of ADT.

Light to moderate exercise, particularly resistance training, helps preserve muscle and reduce fatigue. Scheduling naps, balancing rest and activity, and maintaining good sleep hygiene also contribute to energy levels. If fatigue feels extreme or is accompanied by shortness of breath or palpitations, consult your doctor.

Musculoskeletal pain

Musculoskeletal pain occurred in about 30% of patients. This includes:

    • arthralgia or joint pain
    • back pain
    • pain in the extremity
    • myalgia or muscle pain
    • bone pain
    • neck pain
    • arthritis
    • musculoskeletal stiffness
    • non-cardiac chest pain
    • musculoskeletal chest pain
    • spinal pain
    • musculoskeletal discomfort

Over-the-counter analgesics such as acetaminophen or ibuprofen may relieve mild pain, but persistent or severe pain requires medical evaluation. Maintaining physical activity, stretching, and discussing bone health with your doctor are important since ADT can contribute to bone loss.

Other Reported Side Effects

These were side effects reported in fewer than 10% of people taking Orgovyx:

  • Emotional changes and depression – Some men experience mood swings, decreased motivation, or depression. Talking openly with your physician about mood changes is important. Counseling, support groups, and, if needed, antidepressant medication can improve well-being.
  • Sleep disturbances – Difficulty falling asleep or staying asleep is noted in patient information and can stem from hot flashes, nocturia, or mood changes. Establishing a relaxing bedtime routine and limiting caffeine and screen time before bed may help.
  • Sexual side effects – Reduced libido and erectile dysfunction are common with ADT. Discussing options for managing erectile dysfunction (e.g., phosphodiesterase type 5 inhibitors, vacuum devices, or counseling) may improve quality of life. Partner communication is essential because sexual issues can affect relationships.
  • Breast enlargement – Some individuals notice breast swelling or tenderness. This condition, called gynecomastia, results from hormonal changes. Talk to your provider if breast changes are uncomfortable or persistent. Medications or radiation therapy can sometimes reduce gynecomastia.
  • Hyperhidrosis – Excessive sweating that goes beyond normal heat or activity levels. Wear lightweight, breathable clothing and use clinical-strength antiperspirants. Keeping cool with fans and avoiding triggers like spicy foods or caffeine may help. If sweating is severe, ask your doctor about prescription treatments.
  • Angioedema – Sudden swelling under the skin, often around the face, lips, tongue, or throat. This can be serious if it affects breathing and requires medical attention.
Orgovyx coupons and discounts

Starts from $419.99

Have a prescription?

Choose Pharma Giant for affordable medications and take control of your health with reliable, cost-effective options today!

SAVE 10% with coupon code:

Serious or Less Common Risks

While most Orgovyx side effects are manageable, some reactions warrant immediate medical attention. In clinical trials, serious adverse reactions occurred in about 12% of patients taking Orgovyx. The incidence of serious events was slightly lower than with leuprolide, but careful monitoring remains important.

Cardiovascular events

Androgen-deprivation therapy can affect heart rhythm and cardiovascular health.

In the HERO trial, major adverse cardiovascular events (MACE), which include non-fatal heart attack, non-fatal stroke, or death, occurred in 2.9% of the relugolix group versus 6.2% of the leuprolide group, suggesting a lower risk with Orgovyx but highlighting that serious cardiac events still happen.

The prescribing information reports serious adverse events such as heart attack (0.8%) and irregular heartbeat (0.6%). Therefore:

    • Report chest pain, pressure, or pain radiating to the arms, back, neck, or jaw immediately.
    • If you experience sudden numbness or weakness on one side of the body, difficulty speaking, vision changes, or sudden dizziness, seek urgent care.
    • Monitor blood pressure, cholesterol, and blood sugar regularly, and maintain heart-healthy habits such as not smoking, staying active, and managing weight.

Recognizing early signs of stroke improves outcomes. Seek emergency care immediately if any of these symptoms develop.

Kidney injury

Acute kidney injury occurred in about 0.6% of patients in the clinical trial. Symptoms may include reduced urine output, swelling in the legs or ankles, or sudden shortness of breath. Notify your doctor if you notice these signs. Regular blood tests and urine analyses are essential, especially for those with pre-existing kidney problems or dehydration.

Hemorrhage and bleeding

Bleeding events, including gastrointestinal or internal bleeding, were reported in 0.6% of patients. If you develop unusual bruising, prolonged bleeding from minor cuts, black or bloody stools, or vomiting blood, contact your healthcare provider.

Also, mention any medications that affect blood clotting, such as anticoagulants or nonsteroidal anti-inflammatory drugs, as these may increase bleeding risk.

Hypersensitivity reactions

Post-marketing reports describe angioedema and urticaria (hives). Signs of an allergic reaction include:

    • swelling of the face, lips, mouth, or tongue
    • difficulty breathing
    • rash
    • hives

These reactions may occur at any time during therapy. Stop taking the medication and call emergency services if you experience sudden swelling or difficulty breathing.

Long-term bone health

Sex hormones help keep our bones strong. They support the cells that build bone and limit the cells that break bone down. When hormone levels drop, it can lead to rapid bone loss.

Men starting ADT can begin losing bone density within the first 6 to 12 months. Those on continuous treatment can lose up to 10% of their bone density over two years. Hip and spine fractures were especially more common.

In a large US claims database study, men who received a GnRH agonist had a 21% higher risk of any fracture, a 76% higher risk of hip fracture, and an 18% higher risk of vertebral fracture compared to men who did not receive a GnRH agonist.

Healthcare providers often order bone density scans before and during treatment to monitor bone health. If osteoporosis is detected, they may prescribe bisphosphonate drugs and recommend calcium and vitamin D supplements.

Weight-bearing exercises such as walking, dancing, or gentle resistance training strengthen bones. Avoid smoking and maintain a diet rich in calcium and vitamin D.

Here’s an exercise guide for men receiving androgen deprivation therapy:

If you do NOT have osteoporosis

Aim for regular movement

    • Try to get 30 to 60 minutes of moderate activity on most days.
    • You can break it into sessions of at least 10 minutes at a time.
    • Slowly increase how long and how hard you exercise based on what feels manageable.

Include bone-supporting activities

    • Do weight-bearing cardio like walking, hiking, dancing, or cycling 4 to 7 days per week.
    • Add strength and balance exercises 2 to 4 days per week.
        • Examples: weight training, stair climbing, wall push-ups, sit-to-stand exercises.
If you have osteoporosis or are at high risk

Focus on safe, bone-friendly exercise

    • Choose weight-bearing aerobic exercise, resistance training, or a mix of both.
    • Make sure activities match your age and current fitness level.

If you are at risk of falling

    • Practice balance training, such as tai chi.
    • Add structured balance and walking exercises to improve stability.

If you’ve had a spine fracture

    • Prioritize core-strengthening exercises to improve posture and trunk support.

Your exercise plan should be individualized. Work with your doctor, physical therapist, or bone health team to decide the safest and most effective program for you.

Fertility and pregnancy considerations

Orgovyx is intended for male patients, but it can harm an unborn baby. The prescribing information states that relugolix can cause fetal harm and recommends that men with female partners of reproductive potential use effective contraception during treatment and for two weeks after the final dose.

Relugolix may also impair fertility. Since testosterone is needed for normal sperm production, suppressing it may lead to temporary or possibly long-lasting infertility.

If having children in the future is important to you, talk with your healthcare provider before starting treatment. Options such as sperm banking may be discussed.

Tips for Managing Orgovyx Side Effects

Living with ADT can be challenging, but proactive management improves quality of life. Here are practical steps:

  • Stay active – Regular physical activity reduces fatigue, maintains muscle mass, supports bone health, and improves mood. Aim for 30 minutes of exercise most days, combining aerobic and resistance training.
  • Eat a balanced diet – Choose whole grains, lean proteins, fruits, and vegetables. Limit sugary and high-fat foods to manage weight and blood lipids. Consider seeing a dietitian for personalized advice.
  • Monitor your health – Keep track of blood pressure, glucose, cholesterol, and weight. Schedule regular lab tests for liver and kidney function. Discuss bone density scans with your doctor.
  • Discuss medications – Inform your doctor about all prescriptions, over-the-counter drugs, and supplements. Orgovyx can interact with medications that affect P-gp or CYP3A pathways, so dose adjustments or alternative therapies may be needed.
  • Stay hydrated and eat fiber – Drinking plenty of water and eating fiber-rich foods can prevent constipation and help manage diarrhea. Over-the-counter remedies may be appropriate for persistent symptoms.
  • Seek emotional support – Mood changes are common. Support groups, counseling, and open communication with loved ones can help. If depression or anxiety becomes severe, ask your doctor about therapy or medication.
  • Protect your bones – Engage in weight-bearing exercise, avoid smoking, and limit alcohol. If your doctor diagnoses osteopenia or osteoporosis, take prescribed bone-strengthening medications and supplements.
  • Know when to call your doctor – Chest pain, sudden weakness, vision changes, swelling of the face or throat, persistent diarrhea or constipation, and signs of infection require prompt medical attention.

Bottom Line

Orgovyx (relugolix) offers an oral alternative to injectable androgen deprivation therapies for advanced prostate cancer. Clinical trials show that it effectively suppresses testosterone and may reduce the risk of major cardiovascular events compared with some injections.

Most people experience manageable side effects such as hot flashes, metabolic changes, and fatigue, while serious reactions like heart attack, stroke, or kidney injury are less common.

Understanding possible side effects helps you stay alert to changes in your body, adjust your lifestyle when needed, and seek care early. Always talk to your doctor about any concerns, and do not stop or change your medication without medical advice.

Related Articles

Frequently Asked Questions

Most side effects, such as hot flashes, fatigue, or mild gastrointestinal symptoms, continue while you are taking the medication because they are related to lowered testosterone levels. After stopping Orgovyx, testosterone usually begins to recover within weeks, and many side effects gradually improve. In the HERO trial, testosterone recovery was faster compared with some injectable hormone therapies. The exact timeline varies by individual.

Avoid strong P-glycoprotein inhibitors or inducers, such as certain antifungals, antibiotics, or seizure medications, unless your doctor adjusts your treatment. St. John’s wort should also be avoided because it can reduce relugolix levels. Always inform your provider about all prescription drugs, over-the-counter products, and supplements. There are no specific food restrictions listed in the prescribing information.

When you discontinue Orgovyx, testosterone levels typically begin to rise again. In clinical studies, many men experienced recovery of testosterone within about three months. As hormone levels normalize, side effects related to low testosterone may lessen. Your cancer management plan should always be discussed with your oncologist before stopping treatment.

Relugolix is not commonly associated with severe liver injury. Mild increases in liver enzymes have been reported in some patients, but serious liver toxicity is uncommon based on clinical trial data. Your doctor may monitor liver function if clinically indicated. Always report symptoms such as yellowing of the skin or dark urine.

Orgovyx is not known to cause direct kidney damage in most patients. Clinical studies did not show significant kidney toxicity as a common issue. Dose adjustment may be considered in severe kidney impairment. Your healthcare provider will review kidney function as part of routine care.

Orgovyx is taken once daily, with or without food. The most important factor is taking it at the same time each day to maintain steady drug levels. Choose a time that fits your routine to improve adherence. Do not skip doses unless instructed by your doctor.

In the phase 3 HERO trial, Orgovyx maintained castration-level testosterone suppression in about 96.7% of men through 48 weeks. It was shown to be at least as effective as leuprolide injections for advanced prostate cancer. The study also found a lower risk of major cardiovascular events compared with leuprolide. Individual outcomes depend on disease stage and overall health.

Some patients report insomnia or sleep disturbances, although this is not among the most common side effects. Hormonal changes from testosterone suppression can contribute to night sweats or hot flashes, which may disrupt sleep. If sleep problems persist, discuss management options with your doctor.

Orgovyx lowers testosterone to castrate levels, which can reduce the stimulation of prostate cancer cells. While it does not directly shrink the prostate like certain BPH medications, lowering testosterone may reduce tumor size in hormone-sensitive prostate cancer. Imaging and PSA levels are used to monitor response. Your oncologist will track disease progression.

No. Orgovyx is a gonadotropin-releasing hormone receptor antagonist, which works by suppressing testosterone production. It is a form of hormone therapy, not chemotherapy. Chemotherapy drugs kill rapidly dividing cells, whereas Orgovyx blocks hormonal stimulation.

Hormone therapy in general can increase cardiovascular risk, especially in men with pre-existing heart disease. However, in the HERO trial, relugolix showed a lower rate of major adverse cardiovascular events compared with leuprolide. Patients with heart conditions should still be monitored closely. Discuss your cardiac history with your provider.

Relugolix has a half-life of about 60 to 65 hours, meaning it takes several days for most of the drug to clear after stopping. However, its hormonal effects may last longer until testosterone production resumes. Drug levels decline gradually over about one to two weeks. Hormonal recovery varies by patient.

Avoid grapefruit or grapefruit juice while taking Orgovyx, as it can increase the drug’s concentration in your body. Always confirm with your healthcare provider if you have concerns about diet or supplements.

Orgovyx dosing includes a 360 mg (three 120 mg tablets) loading dose on the first day, then 120 mg daily. You can take it with or without food. Swallow the tablets whole. Do not crush or chew them.

Sources

Johnson ED, Carroll DG. Venlafaxine and desvenlafaxine in the management of menopausal hot flashes. Pharm Pract (Granada). 2011 Jul;9(3):117-21. Epub 2011 Sep 14. PMID: 24367464; PMCID: PMC3870169. https://pmc.ncbi.nlm.nih.gov/articles/PMC3870169/

Pandya, K. J., Morrow, G. R., Roscoe, J. A., Zhao, H., Hickok, J. T., Pajon, E., Sweeney, T. J., Banerjee, T. K., & Flynn, P. J. (2005). Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. The Lancet, 366(9488), 818–824. https://doi.org/10.1016/s0140-6736(05)67215-7

Wilson, R. L., Taaffe, D. R., Newton, R. U., Hart, N. H., Lyons-Wall, P., & Galvão, D. A. (2021). Using Exercise and Nutrition to Alter Fat and Lean Mass in Men with Prostate Cancer Receiving Androgen Deprivation Therapy: A Narrative Review. Nutrients, 13(5), 1664. https://doi.org/10.3390/nu13051664

Canadian Agency for Drugs and Technologies in Health. (2024, October 1). Clinical review. Relugolix (Orgovyx) – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK610041/

Ross, R. W., & Small, E. J. (2002). Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. The Journal of Urology, 167(5), 1952–1956. https://doi.org/10.1016/s0022-5347(05)65060-4

Smith, M. R., Boyce, S. P., Moyneur, E., Duh, M. S., Raut, M. K., & Brandman, J. (2005). Risk of clinical fractures after Gonadotropin-Releasing hormone Agonist therapy for prostate cancer. The Journal of Urology, 175(1), 136–139. https://doi.org/10.1016/s0022-5347(05)00033-9

Lee, C., Leslie, W., Czaykowski, P., Gingerich, J., Geirnaert, M., & Lau, Y. (2011). A Comprehensive Bone-Health Management Approach for Men with Prostate Cancer Receiving Androgen Deprivation Therapy. Current Oncology, 18(4), 163–172. https://doi.org/10.3747/co.v18i4.746

Fnp, J. T. a. M., & Mpa, S. S. M. P. (2024). Management of Advanced prostate Cancer with Relugolix: Illustrative case scenarios from an Advanced Practice provider perspective. Journal of the Advanced Practitioner in Oncology, 15(1), 43–55. https://doi.org/10.6004/jadpro.2024.15.1.5

About Orgovyx. (n.d.). ORGOVYX. https://www.orgovyx.com/about-orgovyx/